XOMA
XOMA Royalty Corp.
NASDAQ · Healthcare · Biotechnology · US
$40.17
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 36.2M | 52.1M | 28.5M | 4.8M | 6.0M |
| Cost of Revenue | 2.4M | 3.0M | 206.0K | 143.0K | 274.0K |
| Gross Profit | 33.8M | 49.2M | 28.3M | 4.6M | 5.8M |
| Operating Expenses | |||||
| R&D Expense | 468.0K | 1.7M | 2.9M | 143.0K | 153.0K |
| SG&A Expense | 39.8M | 36.1M | 34.5M | 27.2M | 23.2M |
| General & Admin Expense | 39.8M | 36.1M | 34.5M | 25.6M | 23.2M |
| Selling & Marketing Expense | (3.0K) | — | — | 1.6M | — |
| Other Expenses | (11.4M) | (11.0K) | 30.9M | 19.1M | (177.0K) |
| Total Operating Expenses | 28.8M | 37.8M | 68.3M | 46.5M | 23.2M |
| Cost and Expenses | 31.3M | 40.8M | 68.5M | 46.6M | 23.4M |
| Operating Income (EBIT) | 5.0M | 11.4M | (40.0M) | (41.8M) | (17.4M) |
| Non-Operating | |||||
| Interest Income | 843.0K | — | — | — | 694.0K |
| Interest Expense | 12.9M | 13.0M | 13.8M | 569.0K | — |
| Net Interest Income | (12.1M) | (13.0M) | (13.8M) | (569.0K) | 694.0K |
| Other Non-Op Income/Expense | 28.9M | 20.4M | 20.5M | 1.0M | 295.0K |
| Non-Operating Income (excl Interest) | (41.9M) | (33.5M) | (34.3M) | (18.4M) | (295.0K) |
| EBT (Pre-Tax Income) | 33.9M | 31.8M | (19.5M) | (40.8M) | (17.1M) |
| Income Tax Expense | 104.0K | 103.0K | (5.7M) | — | (15.0K) |
| Bottom Line | |||||
| Net Income | 31.5M | 31.7M | (13.8M) | (40.8M) | (17.1M) |
| Earnings from Cont. Ops | 33.8M | 31.7M | (13.8M) | (40.8M) | (17.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 28.2M | 26.2M | (19.3M) | (46.3M) | (22.6M) |
| Per Share | |||||
| Basic EPS | $1.65 | $1.53 | ($1.65) | ($4.04) | ($1.98) |
| Diluted EPS | $1.57 | $1.46 | ($1.65) | ($4.04) | ($1.98) |
| Revenue Per Share | $3.05 | $2.90 | $2.43 | $0.41 | $0.53 |
| Shares | |||||
| Basic Shares Outstanding | 11.9M | 18.0M | 11.7M | 11.5M | 11.4M |
| Diluted Shares Outstanding | 17.4M | 18.0M | 11.7M | 11.5M | 11.4M |
| Profitability Metrics | |||||
| EBITDA | 50.2M | 47.8M | (5.4M) | (22.6M) | (16.8M) |
| D&A | 3.3M | 3.0M | 216.0K | 900.0K | 274.0K |
| EBIT | 46.8M | 44.8M | (5.6M) | (23.5M) | (17.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026